Compare Salesforce Inc (CRM) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Cytokinetics Inc — how do they compare? Salesforce Inc trades at $193.2 (market cap $161.73B), while Cytokinetics Inc trades at $76.34 (market cap $10.63B). The key difference: Salesforce Inc is far larger — about 15.2× Cytokinetics Inc's market cap, and Salesforce Inc pays a 0.89% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CRM | CYTK | |
|---|---|---|
Market Cap | $161.73B | $10.63B |
Sector | Technology | Technology |
52-Week High | $266.23 | $87.26 |
52-Week Low | $150.12 | $34.31 |
Enterprise Value | $191.77B | $10.74B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $197.51, up 2.47% with strong technical momentum as the stock approaches resistance at $200. The company demonstrates robust fundamentals with consistent earnings beats, posting Q1 2026 EPS of $3.88 versus $3.13 expected, and maintains impressive profitability with 77.64% gross margins. Revenue growth accelerated to $37.9B in 2025 with net income reaching $6.2B, while analyst sentiment remains overwhelmingly positive with 76% buy ratings.
Outlook remains favorable with AI-driven growth catalysts and a $230.61 consensus price target offering 17% upside potential. Key risks include competitive pressures in the SaaS sector and market volatility from AI disruption concerns. The stock presents a compelling opportunity given its Rule of 44 performance metrics and strong cash flow generation of $13.1B from operations.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
